ClinicalTrials.gg
Enrolling by invitationNCT07411703Updated Feb 17, 2026

Automated Trainer-Based Gait Rehabilitation for Hemiplegic Stroke Patients

An observational study in Stroke, sponsored by Cheng-Hsin General Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Cheng-Hsin General Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
60
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 394 studies in Stroke with a site in Taiwan — 73 open to participants now, 82 under way, 4 of them phase 3. Stroke · Taiwan.

Planned enrollment
42nd of 56
60 · median 100
Started
2025
with 21 others
Observational
57 of 394
8 open now
Primary completion
2028-03
later than 63 of 81 live
Registered
380th of 394
by date

Among the 394 studies in Stroke with a site in Taiwan, this one is the 42nd largest by planned enrollment of the 56 observational ones that give a count, is one of 22 that started in 2025, is one of 57 observational ones, reaches primary completion later than 63 of the 81 other live ones, and was the 380th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

73 of the 394 studies in Stroke with a site in Taiwan are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Stroke with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of an automated mobile gait training device developed based on neurodevelopmental treatment (NDT) principles for patients with hemiplegic stroke. Stroke is a major cause of long-term disability, and many survivors experience impaired walking ability that affects their independence and daily functioning. NDT is a commonly used rehabilitation approach that emphasizes therapist-guided facilitation of normal movement patterns during gait training. However, conventional NDT gait training is physically demanding and time-consuming for therapists, which may limit the amount of repetitive gait practice patients can receive.

To address these limitations, this study introduces a power-assisted gait training device capable of reproducing key therapeutic interventions typically provided by therapists. The system uses synchronized dynamic assistance, auditory cues, and wearable inertial measurement units (IMUs) to support gait training on the ground and facilitate more natural and repetitive walking practice. The IMUs provide objective gait data that are used to evaluate changes in swing-phase symmetry, pelvic rotation amplitude, and walking speed.

The primary goal of this study is to assess changes in these gait parameters following training with the proposed NDT-based assistive device. The study plans to enroll 60 adult stroke survivors (aged 20 and older) over a 3-year period starting from March 26, 2025.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult stroke survivors with hemiplegia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 20 years, first-ever stroke, with Brunnstrom stage III to IV of the affected lower limb motor recovery.
  • Functional Ambulation Category (FAC) level IV.
  • Ability to ambulate on level ground without assistive devices.
  • Ability to understand instructions and cooperate with assessments.

Exclusion criteria

Exclusion Criteria:

  • Presence of severe spinal cord injury or peripheral neuropathy.
  • Unstable gait requiring assistive devices, or participants at high risk of falling.
  • Severe impairment in vision, hearing, or cognition, making them unable to comply with assessments.
  • Lower limb fracture within the past 6 months.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Interventions

  • DeviceNDT Gait Training System

    The intervention consists of an NDT gait training device that replicates therapist-applied techniques through mechanical assistance, combined with synchronized auditory feedback and real-time gait analysis using IMU sensors.

06

What researchers measure

Primary outcomes

  1. Swing phase asymmetry

    Swing-phase asymmetry, defined as the difference in swing-phase proportion between the non-paretic and paretic limbs- will be calculated from toe-off to heel-strike timing within the gait cycle, using the wearable inertial measurement units (IMUs) before and after the NDT gait training intervention .

    Time frame: Baseline (pre-intervention) and post-intervention (immediately after completion of the NDT gait training program).

  2. Pelvic rotation amplitude

    Gait data will be acquired via wearable IMUs before and after the NDT gait training intervention, and the amplitude of pelvic rotation will be derived from axial angular velocity data.

    Time frame: Baseline (pre-intervention) and post-intervention (immediately after completion of the NDT gait training program).

  3. Walking speed

    Walking speed will be quantified during gait using IMU-based measurements, and the average walking speed for each stage will be computed from recorded motor-driven motion data and reported in meters per second (m/s).

    Time frame: Baseline (pre-intervention) and post-intervention (immediately after completion of the NDT gait training program).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Mar 26, 2025
Primary completionEst.
Mar 26, 2028
CompletionEst.
Mar 26, 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07411703
Lead sponsor
Cheng-Hsin General Hospital
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 26, 2025
Primary completion
Mar 26, 2028 (estimated)
Completion
Mar 26, 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Szu-Fu Chen
principal investigator · MD, PhD

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion